Latest Headlines
-
Curium Submits New Drug Application For Lutetium Lu 177 Dotatate Injection
7/9/2024
Curium, a world leader in nuclear medicine, announced today that it has submitted its 505(b)(2) New Drug Application for Lutetium Lu 177 Dotatate Injection, which, if approved by the U.S. Food and Drug Administration (FDA), would be intended for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETS).
-
Certara To Acquire Chemaxon To Strengthen Drug Discovery Software Portfolio
7/9/2024
Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software.
-
NIH Funds Consortium To Accelerate Development Of New TB Treatments
7/8/2024
A new consortium co-led by Weill Cornell Medicine, has been awarded a five-year, $31M grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to accelerate the development of faster, more effective treatment regimens for tuberculosis (TB).
-
Imperial And Crick Cancer Drug Spinout Raises £90M To Begin Clinical Development
7/8/2024
Myricx Bio, a cancer therapy spinout based on research carried out at Imperial and the Francis Crick Institute, has raised £90M ($114M) in investment to move its novel treatments for a range of different tumour types, including breast, lung and gastric cancer, into clinical development.
-
Anacura Acquires OHMX.bio, Adding Multi-Omics For Drug Discovery And Diagnostics To Its Services
7/4/2024
Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology. The acquisition expands the existing anacura group activities at AnaBioTec and Labo Nuytinck towards drug discovery and diagnostics research.
-
Genexine Announces Merger With EPD Biotherapeutics To Strengthen Drug Development Pipeline
7/4/2024
Genexine a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of serious unmet medical needs, announced a merger with EPD Biotherapeutics (hereinafter referred to as 'EPD Bio'), a company developing an innovative targeted protein degradation (TPD) bioPROTAC platform technology, to strengthen its research workforce with expertise in PROTAC technology and enhance Genexine’s drug pipeline.
-
McGill, Industry, CQDM And Brain Canada Collaborate For Drug Discovery
7/3/2024
A diverse consortium, combining expertise from McGill University, the Quebec government and private industry, has made significant headway in the development of a novel new drug that could alleviate insomnia and neuropathic pain.
-
Owkin, An AI-Biotech Unicorn, Brings Its Cutting-Edge AI To Germany, Austria And Switzerland To Accelerate Research
7/3/2024
Owkin, the first end-to-end AI-biotech unicorn that provides best-in-class AI-driven precision drug discovery, development and diagnostics, has announced its expansion into the DACH region (Germany, Austria and Switzerland) following partnerships with nine of the top centers in the region, including Charité – Universitätsmedizin Berlin, Centre Hospitalier Universitaire Vaudois (CHUV), Universitätsspital Basel, Technische Universität München (TUM), Uniklinikum Erlangen, Universitätsklinikum Leipzig, Inselspital Bern, Universitätsklinik Mannheim-Heidelberg and Medizinische Universität Wien.
-
Inozyme Pharma Announces FDA Fast Track Designation For INZ-701 In ABCC6 Deficiency
7/2/2024
Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to INZ-701 for the treatment of ABCC6 Deficiency.
-
Vertex Announces FDA Acceptance Of New Drug Application For Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment For Cystic Fibrosis
7/2/2024
Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for investigational once-daily vanzacaftor/tezacaftor/deutivacaftor triple combination therapy (vanza triple) for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene responsive to the vanza triple.